Clinical trial

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351

Study summary

ClinicalTrials.gov

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention ELND002 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2010-03-01

PhasePHASE1

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

ELND002DRUG

PlaceboDRUG

Sponsors & collaborators

Elan Pharmaceuticalslead sponsor

Mapped research locations

San AntonioTexas, United States1 CincinnatiOhio, United States1 TampaFlorida, United States1 MontrealQuebec, Canada1 MinneapolisMinnesota, United States1 AuroraColorado, United States1 Salt Lake CityUtah, United States1 AlbuquerqueNew Mexico, United States1 CalgaryAlberta, Canada1 RaleighNorth Carolina, United States1 KnoxvilleTennessee, United States1 FresnoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01144351 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.